Trade Apellis Pharmaceuticals, Inc. - APLS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.12 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 44.33 |
| Open | 44.05 |
| 1-Year Change | -2% |
| Day's Range | 43.76 - 44.95 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jun 29, 2022 | 45.13 | 0.94 | 2.13% | 44.19 | 45.14 | 42.99 |
| Jun 28, 2022 | 44.33 | -1.68 | -3.65% | 46.01 | 46.49 | 44.24 |
| Jun 27, 2022 | 46.33 | 0.40 | 0.87% | 45.93 | 47.01 | 44.15 |
| Jun 24, 2022 | 46.19 | -1.03 | -2.18% | 47.22 | 47.65 | 44.96 |
| Jun 23, 2022 | 46.89 | 2.96 | 6.74% | 43.93 | 46.97 | 43.60 |
| Jun 22, 2022 | 43.90 | 1.44 | 3.39% | 42.46 | 45.12 | 42.46 |
| Jun 21, 2022 | 43.77 | -0.31 | -0.70% | 44.08 | 45.78 | 43.77 |
| Jun 17, 2022 | 44.05 | 1.60 | 3.77% | 42.45 | 44.94 | 42.45 |
| Jun 16, 2022 | 42.82 | 2.53 | 6.28% | 40.29 | 42.89 | 40.29 |
| Jun 15, 2022 | 41.13 | 3.17 | 8.35% | 37.96 | 41.79 | 37.96 |
| Jun 14, 2022 | 38.79 | -0.40 | -1.02% | 39.19 | 39.51 | 37.67 |
| Jun 13, 2022 | 39.30 | -0.15 | -0.38% | 39.45 | 39.98 | 37.56 |
| Jun 10, 2022 | 41.08 | 1.03 | 2.57% | 40.05 | 41.86 | 40.05 |
| Jun 9, 2022 | 41.65 | -1.31 | -3.05% | 42.96 | 43.48 | 41.37 |
| Jun 8, 2022 | 43.78 | -1.31 | -2.91% | 45.09 | 45.56 | 43.20 |
| Jun 7, 2022 | 45.06 | 3.07 | 7.31% | 41.99 | 45.16 | 41.96 |
| Jun 6, 2022 | 43.12 | -2.57 | -5.62% | 45.69 | 46.96 | 42.71 |
| Jun 3, 2022 | 45.43 | 4.73 | 11.62% | 40.70 | 45.53 | 40.70 |
| Jun 2, 2022 | 42.51 | 2.45 | 6.12% | 40.06 | 43.58 | 40.06 |
| Jun 1, 2022 | 41.30 | -0.10 | -0.24% | 41.40 | 43.33 | 40.16 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam''s base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.| Industry: | Biopharmaceuticals |
100 Fifth Avenue
WALTHAM
MASSACHUSETTS 02451
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com